International Journal of Pharmaceutical Sciences and Drug Analysis
2022, Vol. 2, Issue 1, Part A
Preclinical screening techniques used in pharmacological evaluation of new drug for COVID-19 treatmentAuthor(s):
Ravindra C Sutar, Snehal A Gavhane and Aditi T GadeAbstract:
A Novel Coronavirus is a Severe Acute Respiratory Syndrome Coronavirus 2 also known as SARS-CoV-2 appeared in Wuhan, Hubei Province, China, in December 2019 causing a syndrome termed by World Health Organization in February 11, 2020 and recognized as pandemic on March 11, 2020. It is basically a virus-induced inflammatory disease of airways and lungs that causes severe respiratory issues. The virus has characteristics such as long incubation period, rapid transmission and strong pathogenicity. As humans do not have pre-existing immunity to SARS- CoV-2 there was urgent need to develop therapeutic techniques for SARS-CoV-2, it evoked tremendous investigative effort mainly for the clinical studies, choosing right animals for testing animal models. Studies mentioned include comparison of existing drugs, animal models, newly developed models for COVID-19 also includes testing of safety background for predisposing chronic diseases and development of new treatment and prevention measures. They summarize clinical trial research and discuss new strategies to be used in multiple trials aiming to increase the reliability of results which may in turn help in developing better COVID-19 clinical treatment practices.Pages: 06-08 | Views: 243 | Downloads: 116Download Full Article: Click Here
How to cite this article:
Ravindra C Sutar, Snehal A Gavhane, Aditi T Gade. Preclinical screening techniques used in pharmacological evaluation of new drug for COVID-19 treatment. Int J Pharm Sci Drug Anal 2022;2(1):06-08.